News | 12 June 2022
Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Cantourage introduces second Clever Leaves medical cannabis product to the German market
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Healthcare is timely and personal – and its delivery should be too
The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Based on a post hoc analysis, fewer required respiratory interventions
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
The company has posted net profit of Rs.165.66 crores for the Financial Year ended March 31, 2022
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Subscribe To Our Newsletter & Stay Updated
